Pharmacologic therapy for persistent pulmonary hypertension of the newborn: As "poly" as the disease itself

Pediatric Critical Care Medicine

Volumn 5, Issue 1, 2004, Pages 94-96

  Oishi, Peter ^a   Fineman, Jeffrey R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; NITRIC OXIDE; VASODILATOR AGENT;

DRUG COMBINATION; HUMAN; NEWBORN; NOTE; PERSISTENT FETUS CIRCULATION;

ADENOSINE; DRUG THERAPY, COMBINATION; HUMANS; INFANT, NEWBORN; NITRIC OXIDE; PERSISTENT FETAL CIRCULATION SYNDROME; VASODILATOR AGENTS;

EID: 1642487231     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/01.PCC.0000103193.92228.39     Document Type: Editorial

References (15)

1. Morin FC III, Stenmark KR: Persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 1995; 151:2010-2032
2. Rabinovitch M: Pathophysiology of pulmonary hypertension. In: Emmanouilides GC, Allen HD, Riemenschneider TA, et al (Eds). Moss and Adams Heart Disease in Infants, Children, and Adolescents. Sixth Edition. Baltimore, MD, Williams & Wilkens, 2001, pp 1311-1346
3. Canadian Inhaled Nitric Oxide Study Group and the NICHD Neonatal Research Network: The neonatal inhaled nitric oxide study in term and near-term infant with hypoxic respiratory failure: A multicenter randomized trial. N Engl J Med 1997; 336:597-604
4. Clark RH, Kueser TJ, Walker MW, et al: Lowdose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000; 342:469-474
5. Abman SH, Shanley PF, Accurso FJ: Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest 1989; 83:1849-1858
6. Shaul PW, Yuhanna IS, German Z, et al: Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. Am J Physiol 1997; 272(5 Pt 1):L1005-L1012
7. Tzao C, Nickerson PA, Russell JA, et al: Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs. Pediatr Pulmonol 2001; 31:97-105
8. Kinsella JP, Torielli F, Ziegler JW, et al: Dipyridamole augmentation of response to nitric oxide. Lancet 1995; 346:647-648
9. Ng C, Franklin O, Vaidya M, et al: Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 2004; 5:10-13
10. Konduri GG, Garcia DC, Kazzi NJ, et al: Adenosine infusion improves oxygenation in term infants with respiratory failure. Pediatrics 1996; 97:295-300
11. Fullerton DA, Agrafojo J, Mcintyre RC Jr: Pulmonary vascular smooth muscle relaxation by cAMP-mediated pathways. J Surg Res 1996; 61:444-448
12. Konduri GG, Mital S: Adenosine and ATP cause nitric oxide-dependent pulmonary vasodilation in fetal lambs. Biol Neonate 2000; 78:220-229
13. Saadjian AY, Paganelli F, Juin MA, et al: Plasma beta-endorphin and adenosine concentration in pulmonary hypertension. Am J Cardio 200; 85:858-863
14. Klein C: Nitric oxide and the other cyclic nucleotide. Cell Signal 2002; 14:493-498
15. Kelly LK, Porta NFM, Goodman DM, et al: Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002; 141:830-832